Pérez R, Cabezas I, Sutra J F, Galtier P, Alvinerie M
Laboratorio de Farmacologia, Facultad Medicina Veterinaria, Universidad de Conception, Chile.
Vet J. 2001 Jan;161(1):85-92. doi: 10.1053/tvjl.2000.0521.
A study was undertaken to evaluate and compare faecal excretion of moxidectin and ivermectin in horses after oral administration of commercially available preparations. Ten clinically healthy adult horses, weighing 390-446 kg body weight (b.w.), were allocated to two experimental groups. Group I was treated with an oral gel formulation of moxidectin at the manufacturer's recommended therapeutic dose of 0.4 mg/kg b.w. Group II was treated with an oral paste formulation of ivermectin at the recommended dose of 0.2 mg/kg b.w. Faecal samples were collected at different times between 1 and 75 days post-treatment. After faecal drug extraction and derivatization, samples were analysed by High Performance Liquid Chromatography using fluorescence detection and computerized kinetic analysis. For both drugs the maximum concentration level was reached at 2.5 days post administration. The ivermectin treatment groups' faecal concentrations remained above the detectable level for 40 days (0.6 +/- 0.3 ng/g), whereas the moxidectin treatment group remained above the detectable level for 75 days (4.3 +/- 2.8 ng/g). Ivermectin presented a faster elimination rate than moxidectin, reaching 90% of the total drug excreted in faeces at four days post-treatment, whereas moxidectin reached similar levels at eight days post-treatment. No significant differences were observed for the values of maximum faecal concentration (C(max)) and time of C(max)(T(max)) between both groups of horses, demonstrating similar patterns of drug transference from plasma to the gastrointestinal tract. The values of the area under the faecal concentration time curve were slightly higher in the moxidectin treatment group (7104 +/- 2277 ng.day/g) but were not significantly different from those obtained in the ivermectin treatment group (5642 +/- 1122 ng.day/g). The results demonstrate that although a 100% higher dose level of moxidectin was used, attaining higher plasma concentration levels and more prolonged excretion and gut secretion than ivermectin, the concentration in faeces only represented 44.3+/- 18.0% of the total parental drug administered compared to 74.3 +/- 20.2% for ivermectin. This suggests a higher level of metabolization for moxidectin in the horse.
开展了一项研究,以评估和比较马匹口服市售制剂后莫西菌素和伊维菌素的粪便排泄情况。10匹临床健康的成年马,体重390 - 446千克,被分配到两个实验组。第一组用莫西菌素口服凝胶制剂,按制造商推荐的治疗剂量0.4毫克/千克体重给药。第二组用伊维菌素口服膏剂,按推荐剂量0.2毫克/千克体重给药。在治疗后1至75天的不同时间采集粪便样本。粪便药物提取和衍生化后,采用荧光检测和计算机动力学分析的高效液相色谱法对样本进行分析。两种药物在给药后2.5天达到最高浓度水平。伊维菌素治疗组的粪便浓度在40天内(0.6±0.3纳克/克)保持在可检测水平以上,而莫西菌素治疗组在75天内(4.3±2.8纳克/克)保持在可检测水平以上。伊维菌素的消除速度比莫西菌素快,在治疗后4天达到粪便中排泄的总药物的90%,而莫西菌素在治疗后8天达到类似水平。两组马之间的最大粪便浓度(C(max))值和C(max)时间(T(max))未观察到显著差异,表明药物从血浆转移到胃肠道的模式相似。莫西菌素治疗组的粪便浓度时间曲线下面积值略高(7104±2277纳克·天/克),但与伊维菌素治疗组获得的值(5642±1122纳克·天/克)无显著差异。结果表明,尽管莫西菌素的剂量水平高出100%,达到的血浆浓度水平更高,排泄和肠道分泌时间比伊维菌素更长,但与伊维菌素的74.3±20.2%相比,粪便中的浓度仅占给药总母体药物的44.3±18.0%。这表明马体内莫西菌素的代谢水平更高。